CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genentech, Inc. v. Regeneron Pharmaceuticals, Inc.

7:11-cv-09463

Overview

Case Number 7:11-cv-09463
Filing Date 2011-12-23
Status Terminated
Termination Date 2013-05-21
Court District Court, S.D. New York (nysd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Both

Parties

Defendant

Sanofi-Aventis Amerique Du Nord S.N.C. Operating Company

Represented By

5 Attorneys Listed

Sanofi-Aventis Amerique Du Nord S.N.C. Operating Company

Represented By

5 Attorneys Listed

Sanofi Operating Company

Represented By

5 Attorneys Listed

Sanofi-Aventis U.S. Inc. Operating Company

Represented By

5 Attorneys Listed

Sanofi-Aventis U.S. LLC Operating Company

Represented By

5 Attorneys Listed

Counter Defendant

Regeneron Pharmaceuticals, Inc. Operating Company

Represented By

8 Attorneys Listed

Third Party Plaintiff

Genentech, Inc. Operating Company

Represented By

6 Attorneys Listed

Court & Judges

Court

District Court, S.D. New York (nysd)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Patents Involved

No asserted patent numbers detected in initial docket filings yet.

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT against Regeneron Pharmaceuticals, Inc., Sanofi, Sanofi-Aventis Amerique Du Nord S.N.C., Sanofi-Aventis U.S. Inc., Sanofi-Aventis U.S. LLC. (Filing Fee $350.00, Receipt Number 465407002232) Document filed by Genentech, Inc. (lnl) (Entered: 12/23/2011)

Entry #1 • 2011-12-23
1
Court Order

STANDING ORDER IN RE PILOT PROJECT REGARDING CASE MANAGEMENT TECHNIQUES FOR COMPLEX CIVIL CASES IN THE SOUTHERN DISTRICT OF NEW YORK (See M-10-468 Order filed November 1, 2011). This case is hereby designated for inclusion in the Pilot Project Regarding Case Management Techniques for Complex Civil Cases in the Southern District of New York (the Pilot Project), unless the judge to whom this case is assigned determines otherwise. This case is designated for inclusion in the Pilot Project because it is a class action, an MDL action, or is in one of the following Nature of Suit categories: 160, 245, 315, 355, 365, 385, 410, 830, 840, 850, 893, or 950. The presiding judge in a case that does not otherwise qualify for inclusion in the Pilot Project may nevertheless designate the case for inclusion in the Pilot Project by issuing an order directing that the case be included in the Pilot Project. The description of the Pilot Project, including procedures to be followed, is attached to this Order. (Signed by Judge Loretta A. Preska on 10/31/2011) (lnl) (Entered: 12/23/2011)

Entry #2 • 2011-12-23
1

NOTICE OF CASE ASSIGNMENT to Judge Vincent L. Briccetti. Judge Unassigned is no longer assigned to the case. (pgu) (Entered: 01/05/2012)

Entry #3 • 2012-01-05
1

RULE 7.1 CORPORATE DISCLOSURE STATEMENT. Identifying Corporate Parent Roche Holdings, Inc. for Genentech, Inc.. Document filed by Genentech, Inc..(Stone, Eric) (Entered: 01/05/2012)

Entry #4 • 2012-01-05
1
Pleading / Complaint

SUMMONS RETURNED EXECUTED Summons and Complaint served. Regeneron Pharmaceuticals, Inc. served on 1/3/2012, answer due 1/24/2012. Service was accepted by Connie Bannon Executive Assistant to the Senior Vice President General Counsel and Secretary. Document filed by Genentech, Inc.. (Stone, Eric) (Entered: 01/06/2012)

Entry #5 • 2012-01-06
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc